Lineage plasticity has emerged as an important mechanism of treatment resistance in
prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss …

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …

Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a
condition known as castration-resistant prostate cancer (CRPC). Acquiring a better …

Curcumin is a polyphenol extracted from the rhizomes of the turmeric plant, Curcuma longa
which has anti-inflammatory, and anticancer properties. Chronic inflammation is associated …

Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a
promising new type of therapeutic agents, but the design of PROTAC degraders with …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …

Lineage plasticity causes therapeutic resistance; however, it remains unclear how the fate
conversion and phenotype switching of cancer-associated fibroblasts (CAFs) are implicated …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …